We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Early Diagnosis of CKD Is Inadequate for High Risk Patients

By Labmedica staff writers
Posted on 14 Jan 2008
The majority of people with diabetes and/or high blood pressure--the two leading causes of chronic kidney disease (CKD)--are not receiving recommended tests to identify this disease early, when medical treatment can slow or halt disease progression. More...
In addition many patients with early-stage CKD are not being well managed for contributing diseases, such as diabetes and hyperlipidemia.

A slightly elevated level of protein in the urine, or microalbuminuria, is one of the earliest markers of kidney disease. The microalbumin test can detect kidney damage when no other symptoms are present, and provides information that can help physicians and their patients determine treatment that can potentially slow disease progression.

A report was based on findings from 6.2 million estimated glomerular filtration rate (eGFR) test and microalbumin test results, the two key indicators of kidney function, performed by Quest Diagnostics Inc. (Lyndhurst, NJ, USA) between November 2005 and October 2006 on 5.2 million patients who saw a healthcare professional. Among patients who had an eGFR result, approximately 19% had a reading of < 60 ml/min/1.73 m, an indicator of kidney disease.

The study, which was conducted in the United States, suggested that there is a failure to implement evidence-based guidelines issued by the U.S. National Kidney Foundation (NKF; New York, NY, USA), American Diabetes Association (ADA; Alexandria, VA. USA), U.S. National Institutes of Health's National Kidney Disease Education Program (NKDEP; Bethesda, MD, USA), and U.S. National Heart, Lung, and Blood Institute (NHLBI; Bethesda MD, USA), which all recommend annual microalbumin testing to check and follow this marker of kidney damage among patients with hypertension, diabetes, cardiovascular disease (CVD), and other CKD risk factors.

"Physicians may believe that their patients are not at risk for chronic kidney disease if their blood glucose, lipids, and/or blood pressure are controlled. This is simply not true,” said Herman Hurwitz, M.D., FCAP, senior medical director, Quest Diagnostics. "Chronic kidney disease is an insidious consequence of these diseases and can progress quickly without routine monitoring. Patients at increased risk for chronic kidney disease should be screened for microalbuminuria at least annually, while those with confirmed microalbuminuria may require even more frequent monitoring depending on their response to treatment. Yet, our data suggest that at-risk chronic kidney disease patients are not being monitored as recommended by established guidelines.”


Related Links:
Quest Diagnosis
National Kidney Foundation
National Institutes of Health's National Kidney Disease Education Program

New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Radial Immunodiffusion Assay
Radial Immunodifusion - C3 ID
New
Rapid Test Reader
DIA5000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The 3D paper-based analytical device has shown high clinical accuracy for adult-onset immunodeficiency (Photo courtesy of National Taiwan University)

Paper-Based Device Accurately Detects Immune Defects in 10 Minutes

Patients with hidden immune defects are especially vulnerable to severe and persistent infections, often due to autoantibodies that block interferon-gamma (IFN-γ), a key molecule in immune defense.... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.